Race Oncology Limited announced execution of an exclusive licence agreement to access U.S. cancer research and treatment organisation City of Hope's intellectual property ("IP") which highlights bisantrene as a potent inhibitor of the human fat mass and obesity-associated protein, or FTO. City of Hope, one of the larger cancer research and treatment centres in the United States and a leading research centre for diabetes and other life-threatening illnesses, encourages the use of its inventions, discoveries and intellectual property for the benefit of the public. These rights granted under the Agreement include the exclusive license of IP potentially arising from a patent application (PCT Application No.

PCT/US2020/043294) ("Patent Application") as filed by City of Hope and know-how relating to data included in the Patent Application ("Know-How"). The Agreement ensures Race's exclusive access to that IP, which the Company believes will construct a transparent path for collaborative research and the downstream commercialisation of FTO inhibitory applications. A summary of the material terms of the Agreement are provided on page 3 of this announcement.